Skip to main content

Advertisement

SpringerLink
Log in

Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far?

  • Review Article
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Background

Cisplatin (CDDP) chemotherapy can cause serious side effects including irreversible and progressive hearing loss. Studies have aimed to assess potential protective strategies; however, systemic treatments have presented variable results, and potential interactions with CDDP have limited clinical trials.

Methods

A review of the literature was performed in order to evaluate clinical trials that have studied a transtympanic approach as an otoprotectant strategy.

Results

Six clinical trials were included. While a transtympanic approach can limit side effects and avoid interactions with CDDP, recurrent issues have been expressed including which otoprotectant to test, time delays between CDDP treatment and transtympanic injections, side effects such as pain and dizziness, concentrations, and number of injections. Clinical trials have used sodium thiosulfate, N-acetylcysteine and dexamethasone.

Conclusions

While a transtympanic approach seems like an attractive strategy, further research is needed to clarify which is the optimal otoprotectant, its dosage, and the number of injections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gold JM, Raja A (2019) Cisplatin (Cisplatinum); [Updated 2020 Feb 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547695/

  2. Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364–369

    PubMed  Google Scholar 

  3. Dille MF, Konrad-Martin D, Gallun F et al (2010) Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study. J Am Acad Audiol 21:409–417

    PubMed  PubMed Central  Google Scholar 

  4. Lucieer F, Vonk P, Guinand N, Stokroos R, Kingma H, van de Berg R (2016) Bilateral vestibular hypofunction: insights in etiologies, clinical subtypes, and diagnostics. Front Neurol 7:26

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Paken J, Govender CD, Pillay M, Sewram V (2019) A review of cisplatin-associated ototoxicity. Semin Hear 40:108–121

    PubMed  PubMed Central  Google Scholar 

  6. Waissbluth S, Chuang A, Del Valle Á, Cordova M (2018) Long term platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol 107:75–79

    PubMed  Google Scholar 

  7. Frisina RD, Wheeler HE, Fossa SD et al (2016) Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 34:2712–2720

    CAS  PubMed  PubMed Central  Google Scholar 

  8. van As JW, van den Berg H, van Dalen EC (2018) Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev Aug 3(8):CD010181

    Google Scholar 

  9. Knight KR, Chen L, Freyer D et al (2017) Group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): a report from the children's oncology group. J Clin Oncol 35:440–445

    PubMed  Google Scholar 

  10. Rybak LP, Mukherjea D, Ramkumar V (2019) Mechanisms of cisplatin-induced ototoxicity and prevention. Semin Hear 40:197–204

    PubMed  PubMed Central  Google Scholar 

  11. Sheth S, Mukherjea D, Rybak LP, Ramkumar V (2017) Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci 11:338

    PubMed  PubMed Central  Google Scholar 

  12. Iwamoto Y, Kawano T, Ishizawa M, Aoki K, Kuroiwa T, Baba T (1985) Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits. Cancer Chemother Pharmacol 15:228–232

    CAS  PubMed  Google Scholar 

  13. Abe R, Akiyoshi T, Baba T (1990) Inactivation of cis-diamminedichloroplatinum (II) in blood by sodium thiosulfate. Oncology 47:65–69

    CAS  PubMed  Google Scholar 

  14. Saito T, Zhang ZJ, Manabe Y, Ohtsubo T, Saito H (1997) The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. Eur Arch Otorhinolaryngol 254:281–286

    CAS  PubMed  Google Scholar 

  15. Muldoon LL, Pagel MA, Kroll RA et al (2000) Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 6:309–315

    CAS  PubMed  Google Scholar 

  16. Neuwelt EA, Brummett RE, Remsen LG et al (1996) In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 56:706–709

    CAS  PubMed  Google Scholar 

  17. Doolittle ND, Muldoon LL, Brummett RE et al (2001) Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493–500

    CAS  PubMed  Google Scholar 

  18. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA (2005) Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314:1052–1058

    CAS  PubMed  Google Scholar 

  19. Harned TM, Kalous O, Neuwelt A et al (2008) Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin Cancer Res 14:533–540

    CAS  PubMed  Google Scholar 

  20. Freyer DR, Chen L, Krailo MD et al (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63–74

    CAS  PubMed  Google Scholar 

  21. Brock PR, Maibach R, Childs M et al (2018) Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med 378:2376–2385

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Wang J, Lloyd Faulconbridge RV, Fetoni A, Guitton MJ, Pujol R, Puel JL (2003) Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology 45:380–393

    CAS  PubMed  Google Scholar 

  23. Wimmer C, Mees K, Stumpf P, Welsch U, Reichel O, Suckfüll M (2004) Round window application of d-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 25:33–40

    PubMed  Google Scholar 

  24. Berglin CE, Pierre PV, Bramer T et al (2011) Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model. Cancer Chemother Pharmacol 68:1547–1556

    CAS  PubMed  Google Scholar 

  25. Dickey T, Muldoon LL, Kraemer DF, Neuwelt EA (2004) Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193:25–30

    Google Scholar 

  26. Lorito G, Hatzopoulos S, Laurell G et al (2011) Dose-dependent protection on cisplatin-induced ototoxicity—an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model. Med Sci Monit 17:BR179–BR186

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Muldoon LL, Wu YJ, Pagel MA, Neuwelt EA (2015) N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. J Neurooncol 12:433–440

    Google Scholar 

  28. Wu YJ, Muldoon LL, Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312:424–431

    CAS  PubMed  Google Scholar 

  29. Somdaş MA, Güntürk İ, Balcıoğlu E, Avcı D, Yazıcı C, Özdamar S (2020) Protective effect of N-acetylcysteine against cisplatin ototoxicity in rats: a study with hearing tests and scanning electron microscopy. Braz J Otorhinolaryngol 86:30–37

    PubMed  Google Scholar 

  30. Choe WT, Chinosornvatana N, Chang KW (2004) Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 25:910–915

    PubMed  Google Scholar 

  31. Mohan S, Smyth BJ, Namin A, Phillips G, Gratton MA (2014) Targeted amelioration of cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 151:836–839

    PubMed  Google Scholar 

  32. Trune DR, Canlon B (2012) Corticosteroid therapy for hearing and balance disorders. Anat Rec (Hoboken) 295:1928–1943

    CAS  Google Scholar 

  33. Waissbluth S, Salehi P, He X, Daniel SJ (2013) Systemic dexamethasone for the prevention of cisplatin-induced ototoxicity. Eur Arch Otorhinolaryngol 270:1597–1605

    PubMed  Google Scholar 

  34. Sun C, Wang X, Chen D, Lin X, Yu D, Wu H (2016) Dexamethasone loaded nanoparticles exert protective effects against Cisplatin-induced hearing loss by systemic administration. Neurosci Lett 619:142–148

    CAS  PubMed  Google Scholar 

  35. Sun C, Wang X, Zheng Z et al (2015) A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration. Int J Nanomedicine 10:3567–3579

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Hill GW, Morest DK, Parham K (2008) Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol 27:1005–1011

    Google Scholar 

  37. Daldal A, Odabasi O, Serbetcioglu B (2007) The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 137:747–752

    PubMed  Google Scholar 

  38. Paksoy M, Ayduran E, Sanlı A, Eken M, Aydın S, Oktay ZA (2011) The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol 28:615–621

    CAS  PubMed  Google Scholar 

  39. Özel HE, Özdoğan F, Gürgen SG, Esen E, Genç S, Selçuk A (2016) Comparison of the protective effects of intratympanic dexamethasone and methylprednisolone against cisplatin-induced ototoxicity. J Laryngol Otol 130:225–234

    PubMed  Google Scholar 

  40. Martín-Saldaña S, Palao-Suay R, Aguilar MR, Ramírez-Camacho R, San RJ (2017) Polymeric nanoparticles loaded with dexamethasone or α-tocopheryl succinate to prevent cisplatin-induced ototoxicity. Acta Biomater 53:199–210

    PubMed  Google Scholar 

  41. Fernandez R, Harrop-Jones A, Wang X, Dellamary L, LeBel C, Piu F (2016) The sustained-exposure dexamethasone formulation OTO-104 offers effective protection against cisplatin-induced hearing loss. Audiol Neurootol 21:22–29

    CAS  PubMed  Google Scholar 

  42. Banerjee A, Parnes LS (2004) The biology of intratympanic drug administration and pharmacodynamics of round window drug absorption. Otolaryngol Clin North Am 37:1035–1051

    PubMed  Google Scholar 

  43. van den Berg JH, Beijnen JH, Balm AJ, Schellens JH (2006) Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev 32:390–397

    PubMed  Google Scholar 

  44. Riga MG, Chelis L, Kakolyris S et al (2013) Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Am J Clin Oncol 36:1–6

    CAS  PubMed  Google Scholar 

  45. Yoo J, Hamilton SJ, Angel D et al (2014) Cisplatin otoprotection using transtympanic l-N-acetylcysteine: a pilot randomized study in head and neck cancer patients. Laryngoscope 124:E87–94

    CAS  PubMed  Google Scholar 

  46. Marshak T, Steiner M, Kaminer M, Levy L, Shupak A (2014) Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg 150:983–990

    PubMed  Google Scholar 

  47. Sarafraz Z, Ahmadi A, Daneshi A (2018) Transtympanic injections of N-acetylcysteine and dexamethasone for prevention of cisplatin-induced ototoxicity: double blind randomized clinical trial. Int Tinnitus J 22:40–45

    PubMed  Google Scholar 

  48. Nasr W, Abdelhady M, El-sayed Abd Elbary M, Nada E (2018) Treatment of CDDP-induced ototoxicity by intra-tympanic corticosteroid injection. Indian J Otol 24:33–37

    Google Scholar 

  49. Rolland V, Meyer F, Guitton MJ et al (2019) A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. J Otolaryngol Head Neck Surg 48:4

    PubMed  PubMed Central  Google Scholar 

  50. Viglietta V, Shi F, Hu QY et al (2020) Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. Invest New Drugs. Mar 10

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Department of Otolaryngology, Pontificia Universidad Católica de Chile, Santiago, Chile

    Sofia Waissbluth

Authors
  1. Sofia Waissbluth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sofia Waissbluth.

Ethics declarations

Conflict of interest

The author declares that she has no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Waissbluth, S. Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far?. Eur Arch Otorhinolaryngol 277, 2413–2422 (2020). https://doi.org/10.1007/s00405-020-06003-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-020-06003-w

Keywords

Search

Navigation